Advair Hfa is a drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. It is protected by 39 US drug patents filed from 2013 to 2018. Out of these, 2 drug patents are active and 37 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 04, 2025. Details of Advair Hfa's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Advair Hfa's patents.

Latest Legal Activities on Advair Hfa's Patents

Given below is the list of recent legal activities going on the following patents of Advair Hfa.

Activity	Date	Patent Number
Critical Events for all Patents
Payment of Maintenance Fee, 12th Year, Large Entity	21 Apr, 2022	US7832351
Expire Patent Critical	14 Feb, 2022	US9861771
Maintenance Fee Reminder Mailed Critical	30 Aug, 2021	US9861771
Payment of Maintenance Fee, 12th Year, Large Entity	13 Aug, 2020	US7500444
Expire Patent Critical	04 May, 2020	US7350676
Maintenance Fee Reminder Mailed Critical	18 Nov, 2019	US7350676
Expire Patent Critical	07 Jan, 2019	US7143908
Maintenance Fee Reminder Mailed Critical	16 Jul, 2018	US7143908
Payment of Maintenance Fee, 8th Year, Large Entity	13 Apr, 2018	US7832351
Payment of Maintenance Fee, 12th Year, Large Entity	14 Feb, 2018	US7107986

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Advair Hfa and ongoing litigations to help you estimate the early arrival of Advair Hfa generic.

Advair Hfa's Litigations

Advair Hfa been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 26, 2001, against patent number US6596260. The petitioner , challenged the validity of this patent, with BRUGGER et al as the respondent. Click below to track the latest information on how companies are challenging Advair Hfa's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US6743413	September, 2015	Terminated-Settled (18 Nov, 2016)	3M Company	Mylan Pharmaceuticals Inc.
US6596260	July, 2001	Decision (25 Sep, 2002)	BRUGGER et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

US patents provide insights into the exclusivity only within the United States, but Advair Hfa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Advair Hfa's family patents as well as insights into ongoing legal events on those patents.

Advair Hfa's Family Patents

Advair Hfa has patent protection in a total of 17 countries. It's US patent count contributes only to 7.1% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Advair Hfa.

Full family tree

Generic Launch

About Advair Hfa

Advair Hfa is a drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. It is used for the long-term maintenance treatment of asthma in patients 12 years of age and older. Advair Hfa uses Fluticasone Propionate; Salmeterol Xinafoate as an active ingredient. Advair Hfa was launched by Glaxo Grp Ltd in 2006.